Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

26.3%

5 terminated/withdrawn out of 19 trials

Success Rate

73.7%

-12.8% vs industry average

Late-Stage Pipeline

42%

8 trials in Phase 3/4

Results Transparency

57%

8 of 14 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 2

8(42.1%)

Phase 3

6(31.6%)

Phase 1

3(15.8%)

Phase 4

2(10.5%)

19Total

Phase 2(8)

Phase 3(6)

Phase 1(3)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT04399395Phase 4Withdrawn

Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery

Role: collaborator

NCT01601704Phase 3Terminated

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Role: lead

NCT02638129Phase 4Terminated

Naltrexone/Bupropion Cardiovascular Outcomes Study

Role: lead

NCT02735603Phase 1Completed

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Role: lead

NCT02745912Phase 1Completed

Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants

Role: lead

NCT01764386Phase 3Completed

Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

Role: lead

NCT00711477Phase 2Completed

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

Role: lead

NCT00456521Phase 3Completed

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

Role: lead

NCT02259179Phase 1Completed

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

Role: lead

NCT00474630Phase 3Completed

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

Role: lead

NCT00532779Phase 3Completed

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

Role: lead

NCT00567255Phase 3Completed

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

Role: lead

NCT00734435Phase 2Terminated

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

Role: lead

NCT00758966Phase 2Terminated

Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder

Role: lead

NCT00709371Phase 2Completed

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

Role: lead

NCT00563563Phase 2Completed

A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

Role: lead

NCT00624858Phase 2Completed

A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression

Role: lead

NCT00364871Phase 2Completed

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

Role: lead

NCT00339014Phase 2Completed

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

Role: lead

All 19 trials loaded